| __timestamp | Alkermes plc | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 7753000 | 1513000 |
| Thursday, January 1, 2015 | 4019000 | 12573000 |
| Friday, January 1, 2016 | 2301000 | 42238000 |
| Sunday, January 1, 2017 | 7232000 | 69800000 |
| Monday, January 1, 2018 | 68895000 | 113773000 |
| Tuesday, January 1, 2019 | 52816000 | 179362000 |
| Wednesday, January 1, 2020 | 1946000 | 266946000 |
| Friday, January 1, 2021 | 1020000 | 438633000 |
| Saturday, January 1, 2022 | 393842000 | 461645000 |
| Sunday, January 1, 2023 | 270806000 | 387332000 |
| Monday, January 1, 2024 | 245326000 | 320653000 |
Unleashing insights
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Alkermes plc and CRISPR Therapeutics AG have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, CRISPR Therapeutics AG consistently increased its R&D spending, peaking in 2022 with a remarkable 461 million USD, reflecting a 30-fold increase from 2014. This surge underscores their aggressive pursuit of cutting-edge gene-editing technologies. In contrast, Alkermes plc's R&D expenditure showed more fluctuation, with a significant spike in 2022, reaching 394 million USD, a 50-fold increase from 2014. This suggests a strategic pivot towards innovation in recent years. As the biotech landscape continues to shift, these spending patterns offer valuable insights into each company's strategic priorities and their potential impact on future breakthroughs.
Eli Lilly and Company or Alkermes plc: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for BeiGene, Ltd. and Alkermes plc
Research and Development Expenses Breakdown: United Therapeutics Corporation vs CRISPR Therapeutics AG
Research and Development Investment: Summit Therapeutics Inc. vs Alkermes plc
Analyzing R&D Budgets: Insmed Incorporated vs CRISPR Therapeutics AG
R&D Spending Showdown: BioMarin Pharmaceutical Inc. vs CRISPR Therapeutics AG
Research and Development: Comparing Key Metrics for Blueprint Medicines Corporation and Alkermes plc
Comparing Innovation Spending: CRISPR Therapeutics AG and Protagonist Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs Mesoblast Limited
CRISPR Therapeutics AG vs Galapagos NV: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.